<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kosmidis, P.A.</style></author><author><style face="normal" font="default" size="100%">Fountzilas, G.</style></author><author><style face="normal" font="default" size="100%">Baka, S.</style></author><author><style face="normal" font="default" size="100%">Samantas, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, A.M.</style></author><author><style face="normal" font="default" size="100%">Gogas, H.</style></author><author><style face="normal" font="default" size="100%">Skarlos, D.</style></author><author><style face="normal" font="default" size="100%">Papacostas, P.</style></author><author><style face="normal" font="default" size="100%">Boukovinas, J.</style></author><author><style face="normal" font="default" size="100%">Bakogiannis, Ch.</style></author><author><style face="normal" font="default" size="100%">Pantelakos, P.</style></author><author><style face="normal" font="default" size="100%">Athanasiou, H.</style></author><author><style face="normal" font="default" size="100%">Misailidou, D.</style></author><author><style face="normal" font="default" size="100%">Tsekeris, P.</style></author><author><style face="normal" font="default" size="100%">N. Pavlidis</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Concurrent chemoradiotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Gemcitabine</style></keyword><keyword><style  face="normal" font="default" size="100%">Non-operable localized NSCLC</style></keyword><keyword><style  face="normal" font="default" size="100%">Paclitaxel</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-37549017106&amp;partnerID=40&amp;md5=d130e55d8341621d5f79ee02f4891104</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">27</style></volume><pages><style face="normal" font="default" size="100%">4391 - 4395</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy following induction with non-platinum chemotherapy in patients with inoperable locally advanced NSCLC. Patients and Methods: All patients with locally advanced inoperable NSCLC ECOG performance status (PS): 0-1 following staging received paclitaxel 200 mg/m2 in a 3-h infusion on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8 every 21 days for two cycles. The patients with a response or stable disease (SD) continued to receive paclitaxel 60 mg/m2 weekly and radiotherapy 63 Gy given at 1.8 Gy once a day for 7 weeks. Results: Forty-three eligible patients entered the study. The median age was 63 years (range 42-76), male 93%, IIIB 63% and IIIA 37%. Following induction 15 (36.5%) of the patients responded: complete response (CR), 2%; partial response (PR), 33%; and 19 (46.5%) SD. From those with SD, 7 (37%) improved to a PR following concurrent chemoradiotherapy. With a median follow-up of 44 months (95% CI: range 36-53) the median survival was 20.8 months (95%c CI: range 15.4-26.3) and time-to-progression 8.4 months (95% CI: range 6.2-10.6). The median survival of those who had improved response from SD to PR was 31.4 months (95% CI: range 18.7-44.1) versus 20.8 months (95% CI: range 5.5-11.3) for those who had no improvement (p=0.20). The commonest grade 3/4 toxicity in induction was neutropenia 12% with 2 febrile neutropenic patients whereas in the concurrent chemoradiotherapy neutropenia, neurotoxicity and oesophagitis were observed in 6% of the patients. Conclusion: Concurrent chemoradiotherapy following induction chemotherapy in patients with stage III NSCLC is feasible with reasonable efficacy and acceptable toxicity.</style></abstract><issue><style face="normal" font="default" size="100%">6 C</style></issue><notes><style face="normal" font="default" size="100%">Cited By :5Export Date: 21 February 2017</style></notes></record></records></xml>